drugset / Trial / NCT05715346

LEV102 Topical Gel in Acquired Blepharoptosis

NCT05715346

Phase 1/2 Completed 33 enrolled Levation Pharma, Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Timeline

Start
2023-02-23
Primary completion
2023-06-24
Completion
2023-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified 1 % Topical
Subject Oxymetazoline Other / unclassified 2 % Topical

Indications